Do acetyl salicylic acid and terbutaline in combination increase the probability of a clinical pregnancy in patients undergoing IVF/ICSI?
The present study investigated if acetyl salicylic acid (ASA) and terbutaline in combination increased the clinical pregnancy rate in patients undergoing in vitro fertilisation (IVF)/intra-cytoplasmic sperm injection (ICSI). A randomised controlled trial was designed, in which 167 patients were randomised to taking ASA for 9 weeks after embryo transfer and terbutaline around the time of embryo transfer as adjuvant medication. A total of 112 patients were randomised to no adjuvant medication. The clinical pregnancy rate per controlled ovarian hyperstimulation was 30.5% in the intervention group and 42.0% in the control group. This difference was not statistically significant, and we conclude that ASA and terbutaline in combination do not increase the clinical pregnancy rate after IVF/ICSI treatment.
Fertilitetsklinikken Sør, Telemark Hospital, Porsgrunn, Norway. hhai@sthf.no
H I
HI
Hanevik
M
M
Friberg
A
A
Bergh
C
C
Haraldsen
J A
JA
Kahn
D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use*; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D057194:Intention to Treat Analysis; D011247:Pregnancy; D018873:Pregnancy Rate; D020554:Sperm Injections, Intracytoplasmic; D013726:Terbutaline / Q000627:therapeutic use*
D058666:Adrenergic beta-2 Receptor Agonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D013726:Terbutaline; D001241:Aspirin